Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
Endocrine Journal · 2024 · 71 (4) · 363-371
DOI: 10.1507/endocrj.ej23-0378 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrine Journal, 2024. Verfasst von Naoki Fukuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan. Hauptthemen laut MEDLINE: Quinolines, Thyroid Neoplasms, Proteinuria, Phenylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Proteinuria has been described as a major on-target adverse event of lenvatinib, although its long-term impact on renal function and clinical outcomes remains unclear. We conducted a retrospective observational study to assess renal function and prognosis in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) receiving lenvatinib. Overall, 70 patients with RR-DTC treated with lenvatinib were enrolled. When proteinuria was observed, the dose and schedule of lenvatinib were adjusted to achieve a urine protein-to-creatinine ratio (UPCR) of less than 3.5 g/gCre according to the study protocols of recent pivotal trials. In total, 50 (71%) and 25 (36%) patients presented with any-grade and grade 3 proteinuria, respectively. Multivariate analysis revealed that age [>65; odds ratio (OR) 8.24, 95% confidence interval (CI) 1.74-39.00, p < 0.01], history of diabetes mellitus (OR 7.79, 95% CI 1.31-46.20, p = 0.02), and hypertension (OR 4.07, 95% CI 1.22-13.60, p = 0.02) were significantly associated with the development of grade 3 proteinuria. Overall, the median estimating glomerular filtration rate (eGFR) gradually decreased every 3 months during treatment. However, no significant deterioration in eGFR was observed in patients with grade 3 proteinuria compared with patients with grades 0-2 proteinuria until 48 months. Patients who developed proteinuria had better survival outcomes than those without proteinuria. In conclusion, the proteinuria grade was not significantly associated with decreased eGFR under UPCR monitoring in our study. Therefore, lenvatinib can carefully be continued targeting UPCR of less than 3.5 g/gCre.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Clinical Cancer Genomics, Hokkaido University Graduate School of Medicine, Sapporo 060-0814, Japan.
- Department of Head and Neck Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
- Department of Chemotherapy and Cancer Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Zitieren
APA
Fukuda, N., Toda, K., Suto, H., Oki, R., Wang, X., Urasaki, T., Sato, Y., Nakano, K., Ono, M., Tomomatsu, J., Mitani, H., & Takahashi, S. (2024). Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine Journal, 71(4), 363-371. https://doi.org/10.1507/endocrj.ej23-0378
Vancouver
Fukuda N, Toda K, Suto H, Oki R, Wang X, Urasaki T, et al. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine Journal. 2024;71(4):363-371. doi:10.1507/endocrj.ej23-0378
BibTeX
@article{Fukuda2024,
author = {Fukuda, Naoki and Toda, Kazuhisa and Suto, Hirotaka and Oki, Ryosuke and Wang, Xiaofei and Urasaki, Tetsuya and Sato, Yasuyoshi and Nakano, Kenji and Ono, Makiko and Tomomatsu, Junichi and Mitani, Hiroki and Takahashi, Shunji},
title = {Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib},
journal = {Endocrine Journal},
year = {2024},
volume = {71},
number = {4},
pages = {363--371},
doi = {10.1507/endocrj.ej23-0378}
}
EUVIMED